Intelligent Bio Solutions Posts 38% Revenue Growth on Cartridge Demand
INBS has more than doubled off its 52-week low of $1.52.
Summary
Intelligent Bio Solutions reported fiscal 2026 full-year revenue growth of 38% year-over-year, driven by expansion of the reader installed base and high-margin cartridge sales. The company also disclosed a $12.4 million net loss and a going concern warning in its 10-K filing. The revenue growth is a bright spot against the wider loss, but the company remains small-cap with ongoing capital needs. Watch for the FDA 510(k) submission outcome, which could be a larger catalyst than the annual results.
At the time of this announcement, INBS was trading at $3.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.7M. The 52-week trading range was $1.52 to $24.90. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.